Pirs stock zacks
Pieris Pharmaceuticals (NASDAQ:PIRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday, Zacks.com reports. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical … PIRS - Pieris Pharma Stock Price - Barchart.com 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. PIRS Stock Price and Chart — NASDAQ:PIRS — TradingView Pieris is in an upward channel and looking bullish. Analyst ratings on the stocks aren't great, but Zacks has given it a HUGE Earnings Surprise Prediction (13.25%!), which should help the stock continue its run until the next report date in early August. Be aware, however, that it is approaching some stiff resistance above $4.60.
What's going on at Pieris Pharmaceuticals (NASDAQ:PIRS)? View breaking news headlines for PIRS stock from trusted media outlets at MarketBeat.
Pieris Pharmaceuticals Stock Price Forecast, PIRS stock price prediction. The best long-term & short-term Pieris Pharmaceuticals share price prognosis for 2020, PIRS / Pieris Pharmaceuticals, Inc. Institutional Ownership File Date, Form, Investor, Opt, Avg Share Price, Shares, Shares Changed (%), Value ($1000), Value 29 Jul 2019 Analysts have been resoundingly optimistic, with all five calling Pieris stock a " strong buy." Plus, its consensus 12-month price target of $7.33 is 18 Feb 2020 The stocks making the biggest moves in premarket trading include Walmart, Apple, for $50 per share, compared to Legg Mason's Friday closing price of $40.72. Pier 1 Imports (PIR) – Pier 1 filed for Chapter 11 bankruptcy 13 Mar 2020 That day the H.C. Wainwright set price target on the stock to $18. $5 suggesting that PIRS could surge by 79.88% from its current share price. Pieris Pharmaceuticals, Inc. - PIRS - Stock Price Today ...
In depth view into PIRS (Pieris Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials.
Nov 11, 2019 · Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.11 per share a year ago. PIRS Pieris Pharmaceuticals, Inc. Stock Quote Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. PIRS - Pieris Pharma News - Barchart.com Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar. Pieris Pharmaceuticals (NASDAQ:PIRS) Lifted to Buy at ...
Earnings Preview: Pieris Pharmaceuticals (PIRS) Q4 ...
Pieris Pharmaceuticals - PIRS - Stock Price & News | The ...
Mar 09, 2020 · Pieris Pharmaceuticals (PIRS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for …
PIRS Stock | PIERIS PHARMACEUTICALS Stock Price Today ... PIRS: Get the latest Pieris Pharmaceuticals stock price and detailed information including PIRS news, historical charts and realtime prices. Recent Analysts’ Ratings Changes for Pieris ... Pieris Pharmaceuticals (NASDAQ: PIRS) has recently received a number of price target changes and ratings updates: 1/27/2020 – Pieris Pharmaceuticals had its price target raised by analysts at HC Wainwright from $7.00 to $9.00. They now have a “buy” rating on the stock. 1/25/2020 – Pieris Pharmaceuticals was downgraded by analysts at Zacks Investment Research […] PIRS News Today (Pieris Pharmaceuticals) | MarketBeat What's going on at Pieris Pharmaceuticals (NASDAQ:PIRS)? View breaking news headlines for PIRS stock from trusted media outlets at MarketBeat.
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates. Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock? Pieris Pharmaceuticals (NASDAQ:PIRS) Lifted to “Buy” at ... ValuEngine upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a hold rating to a buy rating in a research report report published on Wednesday, ValuEngine reports. Other equities analysts have also issued research reports about the company. Zacks Investment Research lowered Pieris Pharmaceuticals from a buy rating to a hold rating in a research note on […] PIRS Stock Price & Charts | Pieris Pharmaceuticals In depth view into PIRS (Pieris Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded ...